NZ577058A - Compositions and methods for treating a neoplasm - Google Patents

Compositions and methods for treating a neoplasm

Info

Publication number
NZ577058A
NZ577058A NZ577058A NZ57705807A NZ577058A NZ 577058 A NZ577058 A NZ 577058A NZ 577058 A NZ577058 A NZ 577058A NZ 57705807 A NZ57705807 A NZ 57705807A NZ 577058 A NZ577058 A NZ 577058A
Authority
NZ
New Zealand
Prior art keywords
antibody
vegf
mice
cell
cancer
Prior art date
Application number
NZ577058A
Other languages
English (en)
Inventor
Robert D Mass
Gregory D Plowman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NZ577058A publication Critical patent/NZ577058A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ577058A 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm NZ577058A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87446006P 2006-12-11 2006-12-11
PCT/US2007/068300 WO2008073509A2 (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm

Publications (1)

Publication Number Publication Date
NZ577058A true NZ577058A (en) 2012-04-27

Family

ID=38521756

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ577058A NZ577058A (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm

Country Status (17)

Country Link
US (1) US20100086544A1 (Direct)
EP (1) EP2099489B1 (Direct)
JP (1) JP2010512407A (Direct)
KR (1) KR101320198B1 (Direct)
CN (1) CN101547705B (Direct)
AU (1) AU2007333565A1 (Direct)
BR (1) BRPI0717688A2 (Direct)
CA (1) CA2670707A1 (Direct)
DK (1) DK2099489T3 (Direct)
IL (1) IL198852A (Direct)
MX (1) MX2009006202A (Direct)
NZ (1) NZ577058A (Direct)
RU (1) RU2482877C2 (Direct)
SG (1) SG177891A1 (Direct)
SI (1) SI2099489T1 (Direct)
WO (1) WO2008073509A2 (Direct)
ZA (1) ZA200903489B (Direct)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02371B (me) * 2006-09-29 2016-06-20 Oncomed Pharm Inc Sastojci i postupci za dijagnstikovanje i tretman raka
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
MY188192A (en) 2011-09-23 2021-11-24 Oncomed Pharm Inc Vegf/dll4 binding agents and uses thereof
EP2825162B1 (en) * 2012-03-14 2018-09-12 Indiana University Research and Technology Corporation Compounds and methods for treating leukemia
WO2014071018A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
GB201409471D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
MX382902B (es) 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
MX377262B (es) 2015-07-27 2025-03-07 Chong Kun Dang Pharmaceutical Corp Compuesto derivado de amida de 1,3,4-oxadiazol como inhibidor de histona desacetilasa 6 y composición farmacéutica que lo contiene.
CA2987570C (en) 2015-07-27 2021-06-15 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
NZ739026A (en) 2015-07-27 2019-03-29 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP3331864B1 (en) 2015-08-04 2021-11-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
FI3362445T3 (fi) 2015-10-12 2023-03-21 Chong Kun Dang Pharmaceutical Corp Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
WO2019147944A1 (en) 2018-01-26 2019-08-01 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disordres using anti-vegf agents
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
JP7451569B2 (ja) 2019-05-31 2024-03-18 チョン クン ダン ファーマシューティカル コーポレーション ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾールホモフタルイミド誘導体化合物、およびそれを含む薬剤学的組成物
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
DK1115704T3 (da) * 1998-09-25 2003-09-29 Boehringer Ingelheim Pharma Substituerede indolinoner med inhiberende virkning for forskellige kinaser og cyclin/CDK komplekser
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6638965B2 (en) * 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
AR069501A1 (es) * 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)

Also Published As

Publication number Publication date
RU2482877C2 (ru) 2013-05-27
RU2009126588A (ru) 2011-01-20
JP2010512407A (ja) 2010-04-22
EP2099489B1 (en) 2014-05-21
WO2008073509A2 (en) 2008-06-19
DK2099489T3 (da) 2014-08-18
CN101547705A (zh) 2009-09-30
CN101547705B (zh) 2013-06-12
KR20090087908A (ko) 2009-08-18
IL198852A (en) 2013-06-27
IL198852A0 (en) 2011-08-01
SI2099489T1 (sl) 2014-09-30
EP2099489A2 (en) 2009-09-16
US20100086544A1 (en) 2010-04-08
MX2009006202A (es) 2009-06-22
ZA200903489B (en) 2010-08-25
AU2007333565A1 (en) 2008-06-19
BRPI0717688A2 (pt) 2013-01-22
SG177891A1 (en) 2012-02-28
WO2008073509A3 (en) 2009-01-08
HK1131064A1 (en) 2010-01-15
KR101320198B1 (ko) 2013-10-30
CA2670707A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
EP2099489B1 (en) Compositions and methods for treating a neoplasm
RU2599447C2 (ru) Моноклональные антетела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи
TW200813090A (en) Combinatorial therapy
CN112203695B (zh) 用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
JP7545983B2 (ja) 抗ｖｅｇｆ抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いてがんを治療する方法
KR20130043168A (ko) 이원 가변 도메인 면역글로불린 및 이의 용도
JP2011504092A (ja) 血管内皮増殖因子（ｖｅｇｆ）の血管新生誘発性アイソフォームに特異的な抗体
WO2018067819A1 (en) Compositions and methods for treatment of cancers
WO2022204581A9 (en) Tgf-beta inhibitors and use thereof
CA3032542A1 (en) Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
KR102428255B1 (ko) 위암의 검출 및 치료를 위한 조성물 및 방법
CN116744970A (zh) 包含sfrp2拮抗剂的组合物和方法
JP2024079697A (ja) 骨の疾患の治療に用いるためのトランスフェリン受容体２のアンタゴニスト及びアゴニスト
JP7590083B2 (ja) 併用療法
CA3213216A1 (en) Tgf-beta inhibitors and use thereof
JP2025523801A (ja) 併用療法
AU2016222436A1 (en) Compositions and methods for treating a neoplasm
AU2014201911A1 (en) Compositions and methods for treating a neoplasm
HK1131064B (en) Compositions and methods for treating a neoplasm
JP2019534314A (ja) エクソン１４スキッピング変異（複数可）またはエクソン１４スキッピング表現型を有するがんの併用療法
CA3164126A1 (en) Antibodies for the treatment of chronic graft versus host disease
HK40045175A (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
HK40007829A (en) Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
EA046745B1 (ru) Способ лечения рака активируемым антителом против pdl1

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 MAY 2017 BY THOMSON REUTERS

Effective date: 20140320

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2018 BY THOMSON REUTERS

Effective date: 20170421

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2019 BY THOMSON REUTERS

Effective date: 20180418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2020 BY THOMSON REUTERS

Effective date: 20190417

LAPS Patent lapsed